Barash NR, Thomas B, Birkenheuer AJ, Breitschwerdt EB, Lemler E, Qurollo BA. Prevalence of *Babesia* spp. and clinical characteristics of *Babesia vulpes* infections in North American dogs. J Vet Intern Med. 2019;33:2075--2081. 10.1111/jvim.15560

CVBD

:   canine vector‐borne disease

IFA

:   immunofluorescence assay

mtLSU

:   *Babesia* mitochondrial large subunit

PCR

:   polymerase chain reaction

1. INTRODUCTION {#jvim15560-sec-0007}
===============

*Babesia vulpes*, a parasite of canids formerly known as *Babesia microti*‐like *Theileria annae* and the *Babesia* "Spanish isolate,"[1](#jvim15560-bib-0001){ref-type="ref"}, [2](#jvim15560-bib-0002){ref-type="ref"}, [3](#jvim15560-bib-0003){ref-type="ref"}, [4](#jvim15560-bib-0004){ref-type="ref"} has been linked to clinical diseases in European dogs including hemolytic anemia, thrombocytopenia, azotemia, and death.[5](#jvim15560-bib-0005){ref-type="ref"}, [6](#jvim15560-bib-0006){ref-type="ref"}, [7](#jvim15560-bib-0007){ref-type="ref"}, [8](#jvim15560-bib-0008){ref-type="ref"} *Babesia vulpes* infections genetically indistinguishable from the *B. vulpes* infections in European dogs are common in both red and gray foxes in North Carolina and Canada.[9](#jvim15560-bib-0009){ref-type="ref"}, [10](#jvim15560-bib-0010){ref-type="ref"} However, *B. vulpes* has been reported only rarely in domestic dogs in the United States of America, making the clinical relevance in domesticated dogs in North America uncertain. *Babesia vulpes* is closely related to the pathogen *B. microti*, which infects humans. *Babesia vulpes* infects a wide range of vertebrate hosts, and based on genetic data and in some cases biologic behavior, it is only distantly related to *Babesia* sensu stricto species (which includes most other *Babesia* species that infect canids).[11](#jvim15560-bib-0011){ref-type="ref"}, [12](#jvim15560-bib-0012){ref-type="ref"}, [13](#jvim15560-bib-0013){ref-type="ref"}, [14](#jvim15560-bib-0014){ref-type="ref"}

The prevalence and role of *B. vulpes* as a cause of disease in dogs[14](#jvim15560-bib-0014){ref-type="ref"} in North America remain unknown. Because commonly utilized commercial polymerase chain reaction (PCR) assays to detect *Babesia* infections in dogs often are designed to amplify *Babesia* sensu stricto species (eg, *B. vogeli*, *B. canis*, *B. rossi*, *B. gibsoni*, and large unnamed *Babesia* spp.), they lack sensitivity for the amplification of *B. vulpes* DNA,[15](#jvim15560-bib-0015){ref-type="ref"} making the detection of this parasite less likely. Our goals were to (1) assess the prevalence of *Babesia* infection in blood and splenic specimens of dogs submitted to a North American diagnostic laboratory using a novel PCR assay designed to amplify *B. vulpes* DNA,[15](#jvim15560-bib-0015){ref-type="ref"} and (2) to describe coinfections and laboratory findings in North American *B. vulpes*‐infected dogs. We hypothesized that *B. vulpes* would be present in North American dogs, and that infected dogs would have clinical signs and laboratory abnormalities consistent with babesiosis as caused by other *Babesia* spp.

2. MATERIALS AND METHODS {#jvim15560-sec-0008}
========================

2.1. Samples and *Babesia* PCR testing {#jvim15560-sec-0009}
--------------------------------------

Ethylenediaminetetraacetic acid‐anticoagulated whole blood or tissue specimens from dogs were submitted to a reference laboratory (Canine Vector‐Borne Disease Diagnostic Panel, Vector Borne Disease Diagnostic Laboratory, North Carolina State University \[NCSU VBDDL\], Raleigh, North Carolina) from June 22, 2015, through June 4, 2018, for canine vector‐borne disease (CVBD) diagnostic testing that included the use of a newly validated *Babesia* quantitative real‐time PCR (qPCR).[15](#jvim15560-bib-0015){ref-type="ref"} Additional follow‐up *Babesia* testing was performed retrospectively for *B. vulpes* PCR‐positive dogs (*B. vulpes*+), for which all *Babesia* PCR primers, gene targets, and associated references are listed in Table [1](#jvim15560-tbl-0001){ref-type="table"}.[3](#jvim15560-bib-0003){ref-type="ref"}, [10](#jvim15560-bib-0010){ref-type="ref"}, [16](#jvim15560-bib-0016){ref-type="ref"} A schematic of sample handling procedures and parasite identification protocols was created (Figure [1](#jvim15560-fig-0001){ref-type="fig"}). Definitions for each *Babesia* species (*B. vogeli*, *B. coco*, *B. gibsoni*, and *B. vulpes*) were established based on PCR (Table [2](#jvim15560-tbl-0002){ref-type="table"}). Briefly, PCR‐positive samples for *Babesia* mitochondrial large subunit (mtLSU) DNA were speciated using at least 4 additional species‐specific (*B. vogeli*, *B. coco*, *B. gibsoni*, and *B. vulpes*) 18S rRNA PCRs. Dogs with positive mtLSU PCRs but negative using the 4 18S rRNA species‐specific PCRs were further screened using *B. canis* 18S rRNA primers, and if they are still negative, the mtLSU amplicon was submitted for sequencing to the NCSU VBDDL. For additional confirmation of *B. vulpes* infections, samples were subjected to an additional PCR that amplified a region of the *B. vulpes* β‐tubulin gene. Amplicons were submitted for sequencing to GENEWIZ Inc (Research Triangle Park, North Carolina) and sequence alignments were made with GenBank sequences using a basic local alignment search tool and AlignX software (Vector NTI Suite 6.0, InforMax, Inc, Bethesda, Maryland).

###### 

Oligonucleotide primers used in this study to amplify *Babesia* DNA

  Organism                                      Target      F (5′‐3′)   R (5′‐3′)                        Ref                                   
  --------------------------------------------- ----------- ----------- -------------------------------- ----------- ------------------------- -------------------------------------------
  *Babesia* genus                               mtLSU       B‐lsu‐F     AGCAAAGTTCCCATTCCAGA             B‐lsu‐R2    TCTTAACCCAACTCACGTACCA    [3](#jvim15560-bib-0003){ref-type="ref"}
                                                            BmicF       TTGCGATAGTAATAGATTTACTGC                                               
  *B. vogeli*                                   18S rRNA    BCV‐F       GTTCGAGTTTGCCATTCGTT             BAB722      ATGCCCCCAACCGTTCCTATTA    [3](#jvim15560-bib-0003){ref-type="ref"}
  *B. coco*                                     18S rRNA    BCO‐F       CCTTTTCTTTGCTTTGTCGC                                                   [3](#jvim15560-bib-0003){ref-type="ref"}
  *B. vulpes*                                   18S rRNA    Bmic18F     CTGCTTTATCATTAATTTCGCTTCCGAACG                                         [3](#jvim15560-bib-0003){ref-type="ref"}
  *B. gibsoni*                                  18S rRNA    BGNC‐F      ACTCGGCTACTTGCCTTGTC                                                   [3](#jvim15560-bib-0003){ref-type="ref"}
  *B. canis*                                    18S rRNA    BCC‐F       TTGCGTTGACGGTTTGACC                                                    [3](#jvim15560-bib-0003){ref-type="ref"}
  *B. vulpes*                                   β‐tubulin   BtubF       GATATGTACCAAGAGCCATTCTTATG       BtubR       TGTTACTCCACTCATAGCAGCAC   [13](#jvim15560-bib-0013){ref-type="ref"}
  *B. gibsoni*                                  cox1        BG‐cox1‐F   CTTCAGCCAATAGCTTTCTGTTTG         BG‐cox1‐R   CCTGAGGCAAGTAAACCAAATAT   [3](#jvim15560-bib-0003){ref-type="ref"}
  *Babesia* genus (bias toward sensu stricto)   18S rRNA    BcanisF     GCATTTAGCGATGGACCATTCAAG         Bcommon2R   TGCTTTCGCAGTAGTTCGTC      [15](#jvim15560-bib-0015){ref-type="ref"}
  *Babesia* genus (bias toward sensu lato)      18S rRNA    Bcanis2F    GCCGGCGATGTATGATTCAAG            Bcommon2R   TGCTTTCGCAGTAGTTCGTC      [15](#jvim15560-bib-0015){ref-type="ref"}

![Schematic of experimental design](JVIM-33-2075-g001){#jvim15560-fig-0001}

###### 

*Babesia* species were defined by positive (+) or negative (−) reactions to polymerase chain reaction (PCR) amplification of broad screening primers (LSU mtDNA), species specific 18S rRNA, or additional PCRs as needed to define and confirm infection

  Species classification                     *Babesia* LSU mtDNA   Specific PCR: 18S rRNA   Additional PCRs                       
  ------------------------------------------ --------------------- ------------------------ ----------------- ---- ---- ---- ---- ----
  *B. vulpes* only                           \+                    −                        −                 \+   −    NA   \+   −
  *B. vulpes* AND *B. gibsoni* coinfection   \+                    −                        −                 \+   \+   NA   \+   \+
  *B. gibsoni*                               \+                    −                        −                 −    \+   NA   NA   NA
  *B. vogeli*                                \+                    \+                       −                 −    −    NA   NA   NA
  *B. coco*                                  \+                    −                        \+                −    −    NA   NA   NA
  *B. canis*                                 \+                    −                        −                 −    −    \+   NA   NA
  *B. conradae*                              \*                    −                        −                 −    −    −    NA   NA

*Notes*: NA indicates that the reaction was not performed. The asterisk indicates that the positive PCR product was sequenced to yield species determination.

2.2. Coinfections for *B. vulpes* infected dogs {#jvim15560-sec-0010}
-----------------------------------------------

For all *B. vulpes*+ samples coinfected with *B. gibsoni*, a region of the *B. gibsoni* cox1 gene was amplified for further confirmation of the coinfection (Table [2](#jvim15560-tbl-0002){ref-type="table"}). For 1 dog coinfected with *B. vulpes* and *B. gibsoni*, conventional PCR amplicons generated from a larger region of the *B. vulpes* 18S rRNA gene (using primers Bcanis2F and Bcommon2R) and *B. gibsoni* 18S rRNA gene (using primers BcanisF and Bcommon2R; Table [1](#jvim15560-tbl-0001){ref-type="table"}) were cloned and sequenced to confirm the findings. Clones were constructed using the pGEM‐T Easy Vector System Promega (Madison, Wisconsin) as recommended by the manufacturer and sequencing was performed as outlined above.

All *B. vulpes*+ dogs (n = 48) were tested using a CVBD PCR panel (NCSU VBDDL) that included testing for *Anaplasma* spp., *Bartonella* spp., *Ehrlichia* spp., hemotropic *Mycoplasma* spp., and *Rickettsia* spp.[15](#jvim15560-bib-0015){ref-type="ref"}, [17](#jvim15560-bib-0017){ref-type="ref"}, [18](#jvim15560-bib-0018){ref-type="ref"}, [19](#jvim15560-bib-0019){ref-type="ref"}, [20](#jvim15560-bib-0020){ref-type="ref"}, [21](#jvim15560-bib-0021){ref-type="ref"} *Babesia vulpes*+ dogs with corresponding serum samples (n = 22) also were tested using an indirect fluorescent antibody test (immunofluorescence assay \[IFA\]) for antibodies against *B. canis* (antigen slides contained both *B. canis* and *B. vogeli* that were isolated from dogs in the United States), *B. gibsoni*, *Bartonella henselae*, *B. koehlerae*, *B. vinsonii berkoffii*, *E. canis*, and *Rickettsia rickettsii* (spotted fever group rickettsia)[17](#jvim15560-bib-0017){ref-type="ref"} and using a SNAP 4DX Plus Test for *Anaplasma* spp., *Ehrlichia* spp., *Borrelia burgdorferi* antibodies and *Dirofilaria immitis* antigen.

2.3. Data analysis {#jvim15560-sec-0011}
------------------

The prevalence of *Babesia* infections was determined in a population of dogs that had *Babesia* PCR testing requested in our diagnostic laboratory between June 22, 2015, and June 4, 2018. All equivocal results and subsequent results from dogs with repeat testing were removed before data analysis. Prevalence in this population refers to the total number of *Babesia* PCR‐positive dogs divided by the total number of individual dogs tested. The submitting veterinarian or diagnostic laboratory was contacted for every *B. vulpes*+ dog to request supporting clinical data. If available, information compiled for *B. vulpes*+ dogs included age, breed, submission zip code, CVBD comprehensive panel results, and available clinicopathologic data consisting of a CBC, serum biochemistry panel, urinalysis, or some combination of these (Table [1](#jvim15560-tbl-0001){ref-type="table"}). Because specimens from *B. vulpes*+ dogs were submitted to various diagnostic laboratories with different reference ranges, each available data point was scored as to whether it was below, within, or above the established reference range for the corresponding diagnostic laboratory.

3. RESULTS {#jvim15560-sec-0012}
==========

3.1. Babesia prevalence {#jvim15560-sec-0013}
-----------------------

Canine whole blood (n = 9345) and tissue (n = 22) samples, representing individual dogs, were submitted to the NCSU VBDDL from June 22, 2015, until June 4, 2018, for CVBD diagnostic testing that included *Babesia* PCR. Of these, 269 (2.9%) dogs were *Babesia* PCR positive by mtLSU amplification. *Babesia gibsoni* (n = 186 dogs, 2.0% prevalence) was the most commonly identified *Babesia* spp. in dogs in these North America samples, followed by *B. vulpes* (n = 48 dogs, 0.51% prevalence), *B. vogeli* (n = 29 dogs, 0.31% prevalence), *B. canis* (n = 18 dogs, 0.19% prevalence), *B. coco* (n = 16 dogs, 0.17% prevalence), and *Babesia conradae* (n = 1 dog, 0.01% prevalence). Of the 48 *B. vulpes*+ dogs, 29 (60%) dogs were coinfected with *B. gibsoni*. Twenty‐two *B. vulpes*+ dogs had both blood and serum samples submitted; of the remaining samples, 17 were submitted as blood only and 9 as splenic tissue samples. One hundred and fifty‐seven *B. gibsoni* positive dogs were not coinfected with *B. vulpes*. No other *Babesia* coinfections were identified.

3.2. *Babesia vulpes*‐positive dogs {#jvim15560-sec-0014}
-----------------------------------

In addition to testing positive based on the *Babesia* mtLSU PCR, all 48 *B. vulpes*‐infected dogs tested positive by *B. vulpes* 18S rRNA and *B. vulpes* β‐tubulin species‐specific PCRs (Table [2](#jvim15560-tbl-0002){ref-type="table"}). All the *B. vulpes* β‐tubulin amplicon sequences were identified as *B. vulpes*. High‐quality sequences for 36 amplicons were aligned and compared to each other and *B. vulpes* reference sequences. One amplicon sequence was 100% (487/487) identical to *B. vulpes* isolate SN87‐1 β‐tubulin gene, originally identified in a fox from Cape Cod, Massachusetts (GenBank Accession \# AY144707), and all other amplicons were 99% (485/487 bases) identical to SN87‐1. Of the *B. vulpes* β‐tubulin amplicons that were 99% identical, 2 different sequences were identified, differing by 2 bases, and were deposited in GenBank (Accession \#s MK697353 and MK697354). Variables such as geographic location or coinfection status were not associated with a particular sequence.

Of the 48 *B. vulpes*+ dogs, 36 samples were submitted from New York State. Other *B. vulpes*+ samples were submitted from Florida (3), Massachusetts (1), North Carolina (4), South Carolina (1), Texas (1), and Wisconsin (1). One sample was submitted from Calgary, Canada, but the dog recently had been relocated from Texas before sample acquisition. Thirty‐six of the 48 *B. vulpes*+ dogs (75%) were managed by a humane organization after being seized as part of animal cruelty investigations or had a known history as a fighting or bait dog. Forty‐four of 48 *B. vulpes*+ dogs (92%) were American Staffordshire or Pit Bull Terrier‐type breeds. The remaining dog breeds included 1 each: Beagle, Dachshund, Schnauzer, Terrier, and an unknown breed. Sex distribution included 13 male intact, 4 male castrated, 12 female intact, 4 female spayed dogs, and 15 dogs of unknown status. Twenty of 48 dogs (42%) were estimated or known to be between 2 and 5 years old, 6 were \<2 years old, 6 were \>5 years old, and 16 were of unknown age.

3.3. Coinfections {#jvim15560-sec-0015}
-----------------

Thirty‐eight (79%) *B. vulpes*+ dogs had evidence of infection with or exposure to other CVBD, determined by a CVBD comprehensive panel (Figure [2](#jvim15560-fig-0002){ref-type="fig"}). Of the 48 *B. vulpes*+ dogs, 29 (60%) were coinfected with *B. gibsoni* based upon PCR testing. For 1 coinfected dog, a larger portion of the 18S rRNA gene with the V4 hypervariable region from both *B. vulpes* and *B. gibsoni* was amplified and cloned. Sequence data obtained from the *B. vulpes* 18S rRNA clone, deposited in GenBank (Accession \# MK693714), was 99% (602/605 bases) identical to several *B. vulpes* 18S rRNA sequences in GenBank, including the "Spanish isolate" strain amplified from a Pit Bull Terrier in Oklahoma (GenBank Accession \# EU583387). Sequence data obtained from the *B. gibsoni* 18S rRNA clone, deposited in GenBank (Accession \# MK694782), was 99% (568/569 bases) identical to *B. gibsoni* genotype Asia, including strains from Midwestern and Eastern United States (GenBank Accession \#s AF205636, AF271081), respectively. Other *B. vulpes*+ CVBD coinfections included 23 (48%) with hemotropic *Mycoplasma* spp. (10 *M. haemocanis* and 13 *Candidatus* Mycoplasma haematoparvum) and 4 (8%) with *Wolbachia*. Within these coinfections, 14 were triply infected with *B. vulpes*, *B. gibsoni*, and a hemotropic *Mycoplasma* spp.

![Venn diagram describing major coinfections found within all dogs positive for either *Babesia vulpes* (n = 48) or *Babesia gibsoni* (n = 186), for a total of 205 dogs infected with either piroplasm](JVIM-33-2075-g002){#jvim15560-fig-0002}

Of the 48 *B. vulpes*+ dogs, 22 (46%) had serum available for IFA and SNAP 4DX Plus serological testing. Six of 22 *B. vulpes*+ dogs (32%) tested by IFA had coexposures with either *Bartonella* (n = 3), *Rickettsia* (n = 1), or *Ehrlichia* (n = 1) spp. The *Ehrlichia* exposure also was detected by SNAP 4DX Plus. *Dirofilaria immitis* infections were detected in 4/22 (18%) dogs, and of those, 2 also were *Wolbachia* PCR positive. Of the 22 *B. vulpes*+ dogs tested by *Babesia* IFA, 14/22 (64%) were *B. canis* and *B. gibsoni* IFA seroreactive, 4/22 (18%) were only *B. canis* IFA seroreactive, and 4/22 (18%) were seronegative to both *B. canis* and *B. gibsoni*. Of the 14 dogs seroreactive to both *B. canis* and *B. gibsoni*, 12 (86%) were also *B. gibsoni* PCR positive. The 4 dogs seroreactive to *B. canis*, but not *B. gibsoni*, were infected with *B. vulpes*.

3.4. Clinical data {#jvim15560-sec-0016}
------------------

Clinicopathologic data were available and collected retrospectively for 14 *B. vulpes*+ dogs, of which 7 were coinfected with *B. gibsoni*, and 9 were coinfected with hemotropic *Mycoplasma* spp. (Table [1](#jvim15560-tbl-0001){ref-type="table"}). Of dogs with available clinical data, 6 were triply infected with *B. vulpes*, *B. gibsoni*, and hemotropic *Mycoplasma*. Four dogs were PCR positive to *B. vulpes* only without evidence of *B. gibsoni* or *Mycoplasma* infection. Common hematologic abnormalities within the *B. vulpes*+ population, independent of coinfection status, included thrombocytopenia, anemia, hyperglobulinemia, hypoalbuminemia, and proteinuria (Table [1](#jvim15560-tbl-0001){ref-type="table"}). Physical examination findings for 5 *B. vulpes*+ dogs were available and are included in the supplemental material (Table [1](#jvim15560-supitem-0001){ref-type="supplementary-material"}).

3.5. Response to treatment {#jvim15560-sec-0017}
--------------------------

Treatment with atovaquone (13.5 mg/kg PO q8h) and azithromycin (10 mg/kg PO q24h) for 10 days[22](#jvim15560-bib-0022){ref-type="ref"}, [23](#jvim15560-bib-0023){ref-type="ref"} was recommended for all dogs as soon as the *B. vulpes* infection was diagnosed. Follow‐up data were available for 9 dogs, all of which were clinically improved after treatment. In total, 6 of 9 *B. vulpes* infections were undetectable by PCR by 90 days after treatment. Four of these dogs were *B. vulpes*+ only (without concurrent *B. gibsoni* infection), and of these, 2 were cleared of *B. vulpes* based on PCR 90 days after treatment. Five treated dogs were coinfected with *B. vulpes* and *B. gibsoni*. Of these, 4 were cleared of *B. vulpes* and 3 were cleared of *B. gibsoni* after treatment. One dog initially coinfected with both *B. vulpes* and *B. gibsoni* was cleared of *B. vulpes* but not of *B. gibsoni* after treatment, and another dog remained positive for both piroplasms after treatment, but follow‐up information was available only at 30 days posttreatment. Of the 2 splenectomized dogs included in the study group, 1 dog coinfected with *B. vulpes* and *B. gibsoni* was PCR negative after 60 days of treatment as mentioned above, and the other, infected with *B. vulpes* but not *B. gibsoni*, was not cleared of *B. vulpes*.

4. DISCUSSION {#jvim15560-sec-0018}
=============

Among the 9376 dogs tested by PCR for *Babesia*, we found an overall *Babesia* prevalence of 2.9%, with *B. vulpes* the second‐most common *Babesia* spp. identified (overall prevalence 0.51%). Our findings indicate that the prevalence of *B. vulpes* is higher than expected in dogs from North America tested diagnostically. Based on sequence analysis of amplified regions of the 18 seconds rRNA and β‐tubulin genes, the strain of *B. vulpes* identified in most of the dogs from our study is 99% identical to a *B. vulpes* strain detected in a Pit Bull in Oklahoma in 2009 and in North American red and gray foxes in 2010.[9](#jvim15560-bib-0009){ref-type="ref"}, [10](#jvim15560-bib-0010){ref-type="ref"}, [24](#jvim15560-bib-0024){ref-type="ref"} Detection of *B. vulpes* in our study most likely was a direct result of the use of novel PCR assays specifically designed to detect a broader range of *Babesia* spp., including *B. vulpes*, rather than a change in the epidemiology of this pathogen. Accurate identification of babesiosis can result in improved patient outcomes because specific treatments for *Babesia* typically are not employed empirically, and treatments recommended for large *Babesia* spp. differ from treatment regimens recommended for small *Babesia* spp. Results obtained before the routine use of PCR assays capable of detecting *B. vulpes* may have resulted in the use of treatments designed for alternate infectious or immune‐mediated etiologies instead of *Babesia* spp.

The natural history of *B. vulpes* infections in dogs remains unknown. The primary routes of transmission for babesiosis in dogs around the world include tick vectors, direct dog‐to‐dog transmission, and inadvertent administration of infected donor blood. The tick vector or vectors for *B. vulpes* transmission have not been definitively identified in any region of the world. We found a high prevalence of *B. vulpes* in American Staffordshire and Pit Bull Terrier‐type dogs that were rescued from alleged dog fighting operations. This epidemiological pattern of *B. vulpes* infection appears very similar to the epidemiology of *B. gibsoni* infections in American Staffordshire and Pit Bull Terrier‐type dogs, in which primary routes of infection are believed to be direct dog‐to‐dog transmission by bite wounds and potentially transplacental transmission. These similarities make it plausible that *B. vulpes* also is being transmitted directly from dog to dog. The role of nonvectored transmission in both the United States and Europe, including vertical and dog‐to‐dog transmission, still requires clarification, as does the role of wild canids as reservoir species for tick acquisition of *B. vulpes* infection.

The presence of a tick vector that is capable of transmitting *B. vulpes* to domestic dogs in North America cannot be excluded. *Ixodes hexagonus*, the hedgehog tick, has been posited as the primary vector in Spain,[25](#jvim15560-bib-0025){ref-type="ref"} but *B. vulpes* has been identified in regions without *I. hexagonus*,[9](#jvim15560-bib-0009){ref-type="ref"} and this tick is not believed to be endemic in North America. *Ixodes scapularis* is known to transmit *B. microti* to rodents and humans, and may serve as a vector for *B. vulpes* organisms. *Babesia vulpes* has been identified recently within unfed *Dermacentor reticulatus* in Austria,[26](#jvim15560-bib-0026){ref-type="ref"} suggesting that other ixodid tick species may transmit these piroplasms.

Our study found a high proportion of dogs coinfected with both *B. vulpes* and *B. gibsoni*. Efforts to amplify multiple species‐specific PCR gene targets were required to confirm that these were true coinfections rather than mis‐amplification of *B. gibsoni* DNA because of lack of PCR primer specificity (Table [2](#jvim15560-tbl-0002){ref-type="table"}). Fighting dogs are known to be at higher risk for coinfections, including both *B. gibsoni* and hemotropic mycoplasmas.[27](#jvim15560-bib-0027){ref-type="ref"} Based on known or suspected vectors, the remaining coinfections and coexposures suggest that some of these dogs were exposed to arthropod vectors including ticks, fleas, or mosquitos.

*Babesia* spp. frequently are reported in coinfections with other vector‐borne disease agents or as mixed *Babesia* infections.[28](#jvim15560-bib-0028){ref-type="ref"}, [29](#jvim15560-bib-0029){ref-type="ref"}, [30](#jvim15560-bib-0030){ref-type="ref"}, [31](#jvim15560-bib-0031){ref-type="ref"} In humans, *B. microti* and *B. burgdorferi* have a synergistic relationship including cotransmission and complex immune modulation.[32](#jvim15560-bib-0032){ref-type="ref"}, [33](#jvim15560-bib-0033){ref-type="ref"} It is unclear whether or not *B. vulpes* and *B. gibsoni* also have such a relationship or if they are simply being cotransmitted in a high‐risk population. Controlled laboratory transmission studies most likely will be required to determine whether complex immunological interactions are more common in coinfected dogs, as compared to dogs infected only with *B. vulpes* or *B. gibsoni*.

Unfortunately, only limited clinical data were available for dogs in our study, and interpretation was confounded by coinfections. Although limited information was available, we observed that dogs infected with *B. vulpes*, with or without concurrent *B. gibsoni* infection, exhibited a range of laboratory abnormalities similar to those previously reported with other *Babesia* spp. infections,[6](#jvim15560-bib-0006){ref-type="ref"}, [22](#jvim15560-bib-0022){ref-type="ref"} including regenerative anemia, thrombocytopenia, hyperglobulinemia, hypoalbuminemia, and proteinuria. Azotemia, although previously reported as a common complication for dogs infected with *B. vulpes* in Europe,[6](#jvim15560-bib-0006){ref-type="ref"} was not common in the dogs in our study.

Complete clinical data were not available for all dogs including physical examination findings, response to treatment, duration of clinicopathologic abnormalities, or long‐term survival rates. In addition, the data were limited to samples submitted to the NCSU VBDDL, which may have created a selection bias toward dogs exhibiting clinicopathologic abnormalities found in association with CVBD and a geographic bias toward the Eastern Atlantic United States, because most samples were submitted from this region.[34](#jvim15560-bib-0034){ref-type="ref"} Regardless of the limitations of our study, *B. vulpes* infects dogs in the United States and causes disease manifestations that are similar to those of other *Babesia* spp. infections.

In conclusion, we found that optimized primers could identify *B. vulpes* infection in dogs that might otherwise have remained undiagnosed. Of 205 dogs diagnosed with either of the 2 piroplasms, 77% had *B. gibsoni* without *B. vulpes* coinfection, 9% had *B. vulpes* without *B. gibsoni* coinfection, and 15% were coinfected with both piroplasms. Whether or not *B. vulpes* has been present as a coinfection in dogs with *B. gibsoni* infections in the United States or other parts of the world remains unknown. If *B. vulpes* infections were present but undetected in dogs with *B. gibsoni*, this coinfection could have affected interpretation of previous reports of dogs with *B. gibsoni* infection. Although clincopathologic data for *B. vulpes*+ dogs was inconsistently available, typical clinical features of babesiosis were reported, and some dogs responded to treatment with atovaquone and azithromycin. *Babesia vulpes* should be considered as a differential diagnosis in dogs showing clinical signs consistent with babesiosis, especially in dogs with *B. gibsoni* infections or in those with extensive cutaneous scarring or in those known to have been involved in dog fighting.
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###### 

**Table S1** Clinical data from B. vulpes infected dogs

For clinicopathologic information, reference ranges are listed in \[gray\]. Values above reference are highlighted in red, below reference in blue, and within reference in gold. Bv = *B. vulpes*; Bgib = *B. gibsoni*

###### 

Click here for additional data file.
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